Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Orexo AB ( (SE:ORX) ) just unveiled an update.
Orexo AB is relocating to new premises in Uppsala Science Park as part of a strategic initiative to enhance its research and development capabilities. This move aims to foster greater collaboration, innovation, and sustainability while offering state-of-the-art laboratories and flexible office spaces. The new location is expected to reduce costs through efficient space utilization and lower energy consumption, thereby strengthening Orexo’s ability to attract and retain talent, which is crucial for developing future innovative medicines.
The most recent analyst rating on (SE:ORX) stock is a Hold with a SEK23.00 price target. To see the full list of analyst forecasts on Orexo AB stock, see the SE:ORX Stock Forecast page.
More about Orexo AB
Orexo is a Swedish pharmaceutical company with three decades of experience in developing improved pharmaceuticals using proprietary formulation technologies. The company focuses on providing innovative treatment solutions for opioid use disorder in the US market and collaborates with leading partners to develop products for other therapeutic areas globally. Orexo is listed on Nasdaq Stockholm and the OTCQX market in the US.
Average Trading Volume: 34,323
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.04B
For detailed information about ORX stock, go to TipRanks’ Stock Analysis page.